Mass-spectrometric MRM analysis of FDA-verified proteins in the blood plasma of healthy volunteers

Novikova S.E.1 , Farafonova T.E.1, Tikhonova O.V.1, Shushkova N.A.1, Pyatnitsky M.A.1, Zgoda V.G.1, Ponomarenko E.A.1, Lisitsa A.V.1, Grigoryev A.I.2, Tutelyan V.A.3, Archakov A.I.1

1. Institute of Biomedical Chemistry, Moscow, Russia
2. Institute of Biomedical Problems, Russian Academy of Sciences, Moscow, Russia
3. Institute of Nutrition, Moscow, Russia
Section: Experimental Study
DOI: 10.18097/PBMC20206604294      PubMed Id: 32893820
Year: 2020  Volume: 66  Issue: 4  Pages: 294-316
The proteomic composition of a biological sample serves as the most important feature of a biological object, and it allows discriminating normal and pathological conditions. Targeted mass spectrometric analysis, namely, multiple reaction monitoring (MRM) using synthetic isotopically-labeled internal standard (SIS), is the main alternative to the ELISA method for the analysis of diagnostically significant proteins. Based on the MRM results, a prototype test system has been developed; it employs the targeted mass spectrometric method for multiplex, quantitative analysis of FDA-verified proteins in whole blood plasma. Using this approach, it was possible to measure the content of 42 proteins in 31 samples in a concentration range spanning five orders of magnitude. The interindividual variability for 30 of the 42 registered proteins was less than 40%. The largest scatter was observed for haptoglobin (68%), immunoglobulin heavy constant delta IGHD (90%), angiotensin (72%), sex hormone-binding globulin SHBG (100%) and lipoprotein-(a) (136%). The obtained results on the concentration of proteins correlate with published data (Hortin et al., 2008, Clinical Chemistry, 54, 1608) with R²=0.84. The developed prototype test system based on targeted mass spectrometric analysis of proteins can be considered as an alternative to methods using monoclonal antibodies.
Download PDF:  
Keywords: SRM analysis, isotope-labeled internal peptide standards, FDA-verified proteins
Supplementary materials:

Novikova, S. E., Farafonova, T. E., Tikhonova, O. V., Shushkova, N. A., Pyatnitsky, M. A., Zgoda, V. G., Ponomarenko, E. A., Lisitsa, A. V., Grigoryev, A. I., Tutelyan, V. A., Archakov, A. I. (2020). Mass-spectrometric MRM analysis of FDA-verified proteins in the blood plasma of healthy volunteers. Biomeditsinskaya Khimiya, 66(4), 294-316.
This paper is also available as the English translation: 10.1134/S1990750821010054
 2024 (vol 70)
 2023 (vol 69)
 2022 (vol 68)
 2021 (vol 67)
 2020 (vol 66)
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)